Citi Global Healthcare Conference

Size: px
Start display at page:

Download "Citi Global Healthcare Conference"

Transcription

1 Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24,

2 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and prospects that constitute forwardlooking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. 2

3 Evolution of BioPharma Strategy Innovative Pharmaceuticals Specialty Care BioPharma

4 BMS R&D Focus Disease Area Focus Drug Platforms Immuno-Oncology Oncology Immunoscience Cardiovascular Small Molecules Biologics Virology Fibrotic Diseases Exploratory Areas Metabolics * Antibody Drug Conjugates Millamolecules * Focus on progressing early-development assets and transitioning late-stage assets to AstraZeneca 4

5 BMY Development Portfolio by Disease Area Data as of Feb 1, 2014 Phase I Phase II Phase Marketed Product III^ Development Anti-LAG3 Anti-CD28 Eldelumab (Anti-IP10) Nivolumab NULOJIX Denenicokin (IL-21) Anti-IL31 Clazakizumab Elotuzumab SPRYCEL ELIQUIS Lirilumab (Anti-KIR) Factor XIa Inhibitor HIV Attachment Inhibitor NS5B Non Nuc ERBITUX BARACLUDE Urelumab (Anti-CD137) IKur Inhibitor NRT Inhibitor Daclatasvir ORENCIA REYATAZ JAK2 Inhibitor PAR4 Antagonist HIV Program ++ Asunaprevir Notch Inhibitors Anti-PD-L1 LPA1 Antagonist Peginterferon lambda-1a Anti-CXCR4 CCR2 / 5 (2) Antagonist CCR2 / 5 (1) Antagonist Anti-CD40L PEG-FGF21 ^In Phase III development or currently under regulatory review ++ Mechanism of Action is not disclosed IO ONC IMM CV Approved in at least one major market (US, EU, JP, CN) VIR FD EA MET 5

6 2013 Pipeline Highlights Cardiovascular Submission of Eliquis VTE prevention and treatment Hepatitis C Submission of daclatasvir and asunaprevir regimen in Japan (DUAL) Submission of daclatasvir in the EU Initiation of Phase III for the daclatasvir / asunaprevir / NS5B fixed dose combination tablet (Triple) Immuno-Oncology Nivolumab monotherapy and combination data at ASCO Nivolumab lung data at WCLC Progression and initiation of several potentially registrational trials Yervoy pooled long-term survival data 6

7 Immuno-Oncology: Transformational Potential Yervoy: first agent to demonstrate long-term survival in some patients with metastatic melanoma Nivolumab: comprehensive development program Multiple tumor types, histologies, and lines of therapy Exploring the role of biomarkers Monotherapy and combination Broad early stage portfolio 7

8 Immuno-Oncology Development Portfolio Phase I Urelumab (Anti-CD137) Cancer HCC Phase II Elotuzumab* 2nd line MM Velcade Combo NHL (FL)^ NHL (DLBCL)^ Cancer (solid tumor) Hematologic Mal. Anti-LAG3 + Cancer Lirilumab + Cancer (solid tumor) Gastric Ovarian Denenicokin + Adolescent melanoma Lirilumab + Glioblastoma^ Cancer (solid tumor) + Cancer (solid tumor) Elotuzumab* Elotuzumab* 2nd line Sq NSCLC 2nd line NSq NSCLC 3rd line Sq NSCLC + SPRYCEL CML^ Unresectable or Metastatic Melanoma Adjuvant Melanoma 1st line Sq NSCLC Small Cell Lung Prostate (posthormonal therapy) 1st line Melanoma 1st line NSCLC (PD-L1 +) Cancer (RCC) 1st line Melanoma 2nd/3rd line RCC + + Metastatic Melanoma Dose Optimization 2nd/3rd line Melanoma Cancer (NSCLC) + Relapsed/Refractory MM Revlimid Combo + Cancer (solid tumor) Approved Indications Registrational 1st line MM Revlimid Combo Data as of Feb 1, 2014 ^ * Development Partnership Nivolumab: Ono Pharmaceuticals; Elotuzumab: AbbVie; Lirilumab: Innate Pharma ^Published on ClinicalTrials.gov, not yet recruiting Abbreviations CML: Chronic Myelogenous Leukemia DLBCL: Diffuse Large B-cell Lymphoma FL: Follicular Lymphoma HCC: Hepatocellular Carcinoma Mal: Malignancy, Met: Metastatic MM: Multiple Myeloma NHL: Non-Hodgkin Lymphoma NSq: Non-Squamous, Sq: Squamous NSCLC: Non Small Cell Lung Cancer RCC: Renal Cell Carcinoma 8

9 Key Data Flow & Events: 2014 Potential approval in VTE treatment in the US and EU Potential approval in VTE prevention in the US Hepatitis C Portfolio Potential approval of daclatasvir and asunaprevir in Japan (DUAL) Potential approval of daclatasvir in the EU Potential submission of daclatasvir and asunaprevir in the US Adjuvant melanoma data Additional combination data with nivolumab Nivolumab (Anti-PD1) Data from Phase II 3 rd line squamous NSCLC Phase I combinations in NSCLC and renal Additional follow-up, including long term survival, from Phase I monotherapy study in lung, renal and melanoma Additional follow-up, including long tem survival, from Phase I combination study with ipilimumab in melanoma Initiation of additional trials and in additional indications Note: Dependent on data availability, acceptance of medical meeting submissions or health authority actions 9

10 Citi Global Healthcare Conference Francis Cuss, MB BChir, FRCP Chief Scientific Officer February 24,

JP Morgan Healthcare Conference

JP Morgan Healthcare Conference JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and

More information

Cowen Health Care Conference

Cowen Health Care Conference Cowen Health Care Conference Francis Cuss, MB BChir, FRCP Senior Vice President, Research March 6, 2013 1 Forward-Looking Information During this meeting, we will make statements about the Company s future

More information

ASCO 2014 Highlights*

ASCO 2014 Highlights* ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s

More information

JP Morgan Healthcare Conference

JP Morgan Healthcare Conference JP Morgan Healthcare Conference Giovanni Caforio Chief Executive Officer January 12, 2016 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects

More information

Cowen Health Care Conference

Cowen Health Care Conference Cowen Health Care Conference Dr. Fouad Namouni Head of Medical March 7, 2016 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute

More information

ESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE

ESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future

More information

ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan

ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,

More information

ASCO 2018 Investor Meeting

ASCO 2018 Investor Meeting ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for

More information

4 th Quarter 2017 Earnings Review & Investor Update

4 th Quarter 2017 Earnings Review & Investor Update 4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking

More information

Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017

Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The

More information

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application. for Opdivo (nivolumab)

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application. for Opdivo (nivolumab) September 3, 2015 U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients (PRINCETON,

More information

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. June 2, 2015 Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial (PRINCETON, NJ, May

More information

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented

More information

Development status of ONO-4538(nivolumab)1

Development status of ONO-4538(nivolumab)1 Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1

More information

Partnering Activity Update

Partnering Activity Update Partnering Activity Update February 2, 2018 Recent Partnering Date Product name / code number Indication / MOA Phase (JP / Overseas) Partner 2010 KYPROLIS / Carfilzomib Multiple Myeloma / Proteasome inhibitor

More information

Development status of OPDIVO (nivolumab) 1

Development status of OPDIVO (nivolumab) 1 August 1, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Filing Approved (US) Non-small cell lung

More information

(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018

(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018 August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of

More information

AACR 2018 Investor Meeting

AACR 2018 Investor Meeting AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for

More information

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018

MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes

More information

Development status of OPDIVO (nivolumab) 1

Development status of OPDIVO (nivolumab) 1 November 2, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Approved Approved(EU) Non-small cell

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. June 2, 2015 Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma (PRINCETON,

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. September 17, 2015 Bristol-Myers Squibb s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Renal Cell Carcinoma (PRINCETON, NJ, September

More information

Cowen Health Care Conference

Cowen Health Care Conference Cowen Health Care Conference Brian Daniels, M.D. Senior Vice President, Global Development and Medical Affairs March 17, 2009 2 During this meeting, we will make statements about the Company s s future

More information

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018

MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018 MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward

More information

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March

More information

Using the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment

Using the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment Using the Mozambique National Quality Policy to Encourage Biomedical Research, Innovation, & Infrastructure Investment Rachael Eckles, JD/MA Director, Regulatory Policy Bristol-Myers Squibb August 10,

More information

Nektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018

Nektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018 Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the

More information

ASCO 2016 * Investor Meeting June 4, *American Society of Clinical Oncology, June 3-7, 2016 ASCO 2016 NOT FOR PRODUCT PROMOTIONAL USE

ASCO 2016 * Investor Meeting June 4, *American Society of Clinical Oncology, June 3-7, 2016 ASCO 2016 NOT FOR PRODUCT PROMOTIONAL USE ASCO 2016 * Investor Meeting June 4, 2016 *American Society of Clinical Oncology, June 3-7, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future plans

More information

Development Pipeline Progress Status. February 1, 2019

Development Pipeline Progress Status. February 1, 2019 Development Pipeline Progress Status February 1, 2019 /9 Development status of OPDIVO (nivolumab) (1) Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy)

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. September 28, 2015 Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma (PRINCETON,

More information

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma Application includes CheckMate -066,

More information

Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150

Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150 Annual Flash Report (unaudited) Fiscal Year ended March 31, 2015 Supplemental Information Status of Development Pipeline as of May 12, 2015 I. Main Pipelines Other than ONO-4538 ⅰ. Developments Status

More information

REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES

REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,

More information

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Reports Second Quarter Financial Results Bristol-Myers Squibb Reports Second Quarter Financial Results Increases Revenues 7% to $4.2 Billion Posts Second Quarter GAAP Loss Per Share of $0.08 and Non-GAAP EPS of $0.53 Achieves Important Regulatory

More information

Merck Pipeline. August 1, 2018

Merck Pipeline. August 1, 2018 Merck Pipeline August 1, 2018 Lead-in Language The chart below reflects the Company s research pipeline as of August 1, 2018. Candidates shown in Phase 3 include specific products and the date such candidate

More information

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. June 22, 2015 European Commission Approves Bristol-Myers Squibb s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

Merck Oncology Overview ASCO 2017

Merck Oncology Overview ASCO 2017 Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking

More information

Merck Pipeline. November 1, 2017

Merck Pipeline. November 1, 2017 Merck Pipeline November 1, 2017 Lead-in Language The chart below reflects the Company s research pipeline as of November 1, 2017. Candidates shown in Phase 3 include specific products and the date such

More information

Building a Fully Integrated Biopharmaceutical Company. June 2014

Building a Fully Integrated Biopharmaceutical Company. June 2014 Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation

More information

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions

More information

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)

More information

FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer

FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer March 5, 2015 FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell Lung Cancer (PRINCETON, NJ, March 4, 2015) Bristol-Myers Squibb Company

More information

Corporate Overview May 8, 2014

Corporate Overview May 8, 2014 0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements

More information

More cancer patients are being treated with immunotherapy, but

More cancer patients are being treated with immunotherapy, but Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH

More information

STEMCENTRX ACQUISITION. April 28, 2016

STEMCENTRX ACQUISITION. April 28, 2016 STEMCENTRX ACQUISITION April 28, 2016 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private Securities

More information

CORPORATE PRESENTATION

CORPORATE PRESENTATION CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

July, ArQule, Inc.

July, ArQule, Inc. July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical

More information

European Commission Approves Expanded Use of Opdivo (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

European Commission Approves Expanded Use of Opdivo (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer April 13, 2016 European Commission Approves Expanded Use of Opdivo (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer (PRINCETON, NJ, April 6, 2016) Bristol-Myers

More information

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated

More information

Clinical: Ipilimumab (MDX-010) Update and Next Steps

Clinical: Ipilimumab (MDX-010) Update and Next Steps Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy

More information

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

AVEO and Astellas Report Final Overall Survival Results from TIVO-1 AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,

More information

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,

More information

TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018

TARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018 NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements

More information

Merck ASCO 2015 Investor Briefing

Merck ASCO 2015 Investor Briefing Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation

More information

Development status of OPDIVO (nivolumab) 1

Development status of OPDIVO (nivolumab) 1 May 12, 2017 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Non-small cell lung cancer (2 nd ~) Approved Approved Approved *) Non-small

More information

Broad and clinically important benefits beyond the initial registrational endpoints are now reported.

Broad and clinically important benefits beyond the initial registrational endpoints are now reported. Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom

More information

Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer

Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer January 20, 2017 Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer (PRINCETON, NJ, January 19, 2017) - Bristol-Myers Squibb Company (NYSE: BMY) announced that it has decided not

More information

Bristol-Myers Squibb s Opdivo

Bristol-Myers Squibb s Opdivo May 9, 2016 Bristol-Myers Squibb s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma

More information

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study

More information

Corporate Presentation March 2016

Corporate Presentation March 2016 Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

First and only FDA-approved combination of two Immuno-Oncology agents 1

First and only FDA-approved combination of two Immuno-Oncology agents 1 Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma First

More information

ArQule Jefferies Global Healthcare Conference June 2015

ArQule Jefferies Global Healthcare Conference June 2015 ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning

More information

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017 GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics

More information

2018 Bank of America Merrill Lynch Healthcare Conference

2018 Bank of America Merrill Lynch Healthcare Conference CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information

More information

Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies

Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies David Feltquate MD, PhD Head of Early Clinical Development, Oncology Bristol-Myers Squibb, Princeton, NJ Challenges

More information

Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting

Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment

More information

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY

More information

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016 ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017

NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017 NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by

More information

Immuno-Oncology Applications

Immuno-Oncology Applications Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures

More information

Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation June 2015

Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells. Corporate Presentation June 2015 Breakthrough Cancer Therapies: Directing the Immune System to Eliminate Tumor Cells Corporate Presentation June 2015 Forward-looking statements / safe harbor This presentation and the accompanying oral

More information

Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma

Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma November 18, 2016 Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma (PRINCETON, N.J., November 12, 2016)

More information

First Presentation of Two-Year Overall Survival Data for Opdivo (nivolumab) in Combination with Yervoy

First Presentation of Two-Year Overall Survival Data for Opdivo (nivolumab) in Combination with Yervoy April 22, 2016 First Presentation of Two-Year Overall Survival Data for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma (PRINCETON,

More information

Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017

Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017 Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,

More information

Advancing Innovative Therapies for Neurological Diseases

Advancing Innovative Therapies for Neurological Diseases Advancing Innovative Therapies for Neurological Diseases Phase 3 Topline Rimegepant 75 mg Zydis ODT December 03, 2018 NYSE: BHVN 2018 Biohaven Pharmaceuticals. All rights reserved. Disclaimer This presentation

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date: Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Five Prime Therapeutics, Inc. Corporate Overview

Five Prime Therapeutics, Inc. Corporate Overview Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities

More information

Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting

Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting Media Release Basel, 5 November 2015 Roche to present new clinical data across a variety of blood diseases at American Society of Hematology 2015 Annual Meeting Gazyva/Gazyvaro (obinutuzumab) and investigational

More information

Janssen Hematologic Malignancy Portfolio

Janssen Hematologic Malignancy Portfolio Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in

More information

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show

More information

Oncology Treatment Trends and Implications for Future Drug Development In China. Presented by Stephanie Hawthorne 16 April 2013

Oncology Treatment Trends and Implications for Future Drug Development In China. Presented by Stephanie Hawthorne 16 April 2013 Oncology Treatment Trends and Implications for Future Drug Development In China Presented by Stephanie Hawthorne 16 April 2013 Economic development, demographic shift, regulatory environment change, industry

More information

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

Developing & Commercializing Targeted Small Molecule Drugs in Cancer Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

May 20, Attached from the following page is the press release made by BMS for your information.

May 20, Attached from the following page is the press release made by BMS for your information. May 20, 2016 European Commission Approves the First and Only Immuno-Oncology Combination, Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen, for Treatment of Advanced Melanoma (PRINCETON, NJ, May 11, 2016)

More information

ARISTOTLE Demonstrated that ELIQUIS is the First Oral Anticoagulant to Significantly Reduce All-Cause Death

ARISTOTLE Demonstrated that ELIQUIS is the First Oral Anticoagulant to Significantly Reduce All-Cause Death ELIQUIS (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial ARISTOTLE

More information

Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma

Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma December 2, 2015 Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma (PRINCETON, NJ, November 27, 2015) Bristol-Myers Squibb Company (NYSE:BMY) announced that the

More information

ICLIO National Conference

ICLIO National Conference ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science

More information

ARQ 087 Overview. FGFR Inhibitor. March 2017

ARQ 087 Overview. FGFR Inhibitor. March 2017 ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform

More information

Jefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer

Jefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this

More information

Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs

Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs Print Page Close Window Press Release Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs $84.0 million of 2014 second quarter net product revenues from

More information

Corporate Presentation October 2018 Nasdaq: ADXS

Corporate Presentation October 2018 Nasdaq: ADXS Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements

More information

Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results

Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results Increases Fourth Quarter Revenues 1% to $4.3 Billion, 4% for Full Year to $16.6 Billion Posts Fourth Quarter GAAP Loss Per

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

European Medicines Agency Validates Bristol-Myers Squibb s Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer

European Medicines Agency Validates Bristol-Myers Squibb s Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer September 21, 2016 European Medicines Agency Validates Bristol-Myers Squibb s Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer (PRINCETON, NJ, September 20, 2016)

More information

Oncology Pipeline Analytics

Oncology Pipeline Analytics Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to

More information

Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018

Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information